by Jessi O'Connell | Mar 6, 2026 | Insights
For compliance specialists across the pharmaceutical and medical device supply chain, the Drug Supply Chain Security Act (DSCSA) has long been viewed as a phased journey. Requirements were introduced incrementally, enforcement timelines shifted, and many organizations...
by Jessi O'Connell | Feb 19, 2026 | Insights
State licensing requirements continue to evolve across the pharmaceutical and medical device landscape. New rules, updated interpretations, revised application forms, and changing renewal timelines can all affect a company’s ability to operate compliantly. For...
by Jessi O'Connell | Feb 11, 2026 | Insights
For pharmaceutical manufacturers, wholesale distributors, 3PLs, repackagers, reverse distributors, and medical device companies, state license renewals are often viewed as routine paperwork. A deadline to track. A form to submit. A fee to pay. But in reality, state...
by Jessi O'Connell | Jan 29, 2026 | Insights
Drug price transparency reporting remains one of the most challenging compliance obligations for pharmaceutical companies. While these requirements have been in place for several years, state legislatures and regulatory agencies continue to refine their expectations,...
by Jessi O'Connell | Jan 22, 2026 | Insights
The Drug Supply Chain Security Act (DSCSA) has been a focal point for the pharmaceutical industry for years. While much of the early effort centered on systems, data exchange, and stabilization, compliance expectations have clearly shifted. Regulators are no longer...
by Jessi O'Connell | Jan 15, 2026 | Insights
The pharmaceutical and medical device supply chain looks very different today than it did even a decade ago. What was once a more linear path from manufacturer to distributor has evolved into a highly interconnected network of partners, facilities, and outsourced...
